Fintel reports that on March 12, 2025, LifeSci Capital initiated coverage of Monte Rosa Therapeutics (NasdaqGS:GLUE) with a ...

Lifesci Capital assumed coverage on shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) in a research report issued to clients and investors on Wednesday, Marketbeat reports. The ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunome (IMNM – Research Report) and Monte Rosa ...

LifeSci Capital initiated coverage of Monte Rosa Therapeutics (GLUE) with an Outperform rating and $19 price target Optimize Your Investment ...

Monte Rosa will remain responsible for completion of the ongoing Phase 1 clinical study of MRT-6160 and is also eligible to ...

One of Monte Rosa Therapeutics' main differentiating factors is its proprietary QuEEN platform to design new molecular glue degraders. This process also leverages AI. They now have two important ...

Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that includes a $50 million ...

The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion. The partnership ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...